BioMarin Pharmaceutical Inc.
BMRN · FY2025 · Fiscal year ended Dec 31, 2025 · 10-K filed Feb 2026
Open the dashboardInfographicSummary
FY2025 key figures
| $ | FY2025 | FY2024 | Change |
|---|---|---|---|
| Revenue | $3.22B | $2.85B | +12.9% |
| Operating income | $409M | $484M | −15.4% |
| Net income | $349M | $427M | −18.3% |
Latest quarter: Q3 2026
Form 10-Q · Three months ended Sep 30, 2026 · filed Nov 3, 2026
| $ | Q3 2026 | Year earlier | Change |
|---|---|---|---|
| Revenue | $1.02B | $776M | +32.0% |
| Operating income | −$82.1M | −$46.7M | −75.8% |
| Net income | −$123M | −$30.7M | −300% |
Q3 2026 dashboardQ3 2026 infographic
Questions
- What was BioMarin's revenue in FY2025?
- $3.22B in FY2025 (Fiscal year ended Dec 31, 2025), +12.9% vs $2.85B a year earlier, per its 10-K filed Feb 2026.
- Was BioMarin profitable in FY2025?
- Yes: net income was $349M and operating income $409M in FY2025.
- What was BioMarin's revenue in Q3 2026?
- $1.02B (+32.0% vs a year earlier), per its Form 10-Q filed Nov 3, 2026.